ILNS News 0.0072 04/28/2014 05:39:25 Intellect Neuroscien (I

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intellect Neuroscien (ILNS) 0.0072 $ILNS

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying
GlobeNewswire - Thu Jan 16, 2:19AM CST
via PRWEB - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates
GlobeNewswire - Thu Nov 14, 1:15PM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is in relation to TOC-1, a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates which are important pathological components in Alzheimer's disease (AD) and other neurodegenerative tauopathies. Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University.

OTC Daily Alert Stock Watch - Intellect Neurosciences, Inc. (OTCQB:ILNS)
WorldStockWire - Tue Aug 13, 6:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Intellect Neurosciences Retains Chain Pharmaceuticals LLC
GlobeNewswire - Tue Jul 30, 10:30AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.

Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Thu Jun 20, 8:25AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Elliot Maza, a member of the Board of Directors of the company.

NY biotech financier gets prison for stock scheme
By LARRY NEUMEISTER - AP - Thu May 02, 7:35PM CDT
NEW YORK (AP) — A federal judge displayed anger as she handed down a four-year prison sentence Thursday to a biotechnology financier who was once among the nation's wealthiest people.

Intellect Neurosciences Issues Letter to Shareholders
GlobeNewswire - Fri Mar 29, 8:35AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
GlobeNewswire - Thu Feb 28, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.

Market Maker Surveillance Report. DVAX, FCX, PSSI, CIM, S, ILNS, Highest Net Sell Volume and Negative Price Friction For Tuesday, February 19th 2013
M2 - Wed Feb 20, 2:23AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3840 companies with "abnormal" market making, 3574 companies with positive Friction Factors and 2220 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dynavax Technologies Corp (NASDAQ VAX), Freeport-McMoRan Copper & Gold Inc (NYSE:FCX), PSS World Medical Inc (NASDAQ SSI), Chimera Investment Corp (NYSE:CIM), Sprint Nextel Corp (NYSE:S), INTELLECT NEUROSCIENCES INC (OTC:ILNS). To access Friction Factor, Naked

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody
GlobeNewswire - Thu Feb 07, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials
Marketwire - Wed Jan 30, 7:08AM CST
During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.

Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
GlobeNewswire - Wed Jan 02, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12 Alzheimer's Drug Development Summit in Neurotech Insights magazine. Dr. Chain was a Distinguished Speaker at the conference.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading